Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/45553
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSghendo, Lino-
dc.contributor.authorMifsud, Janet-
dc.date.accessioned2019-08-14T09:29:15Z-
dc.date.available2019-08-14T09:29:15Z-
dc.date.issued2012-
dc.identifier.citationSghendo, L., & Mifsud, J. (2012). Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. Journal of Pharmacy and Pharmacology, 64(3), 317-325.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/45553-
dc.description.abstractObjectives: Serotonin is a monoamine neurotransmitter that is widely distributed in the body and plays an important role in a variety of psychological and other body functions such as mood, sexual desire and function, appetite, sleep, memory and learning, temperature regulation and social behaviour. This review will assess the use of fluoxetine, one of the most commonly used selective serotonin reuptake inhibitors, as a model for understanding the molecular pharmacology of the serotoninergic system. Key findings: Seven serotonin receptor families have been discovered to date. All serotonin receptors, except 5-HT 3, are G-protein coupled, seven transmembrane receptors that activate an intracellular second messenger cascade. The 5-HT 3 receptor is a ligand-gated ion channel. Furthermore, 5-HT 1A receptors are known as autoreceptors since their stimulation inhibits the release serotonin in nerve terminals. A transporter protein found in the plasma membrane of serotonergic neurones is responsible for the reuptake of this neurotransmitter. Selective serotonin reuptake inhibitors, such as fluoxetine, act primarily at the serotonin transporter protein and have limited, if any, reaction with other neurotransmitter systems. Selective serotonin reuptake inhibitors appear to bind with the serotonin transporter with different rates of occupancy, duration and potency. Summary: The following review focuses on the interaction of serotonin with this membrane transporter in the body and assesses the use of fluoxetine as a reference drug in the understanding of this interaction.en_GB
dc.language.isoenen_GB
dc.publisherWiley Online Libraryen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectSerotoninen_GB
dc.subjectSerotonin uptake inhibitors -- Pharmacologyen_GB
dc.subjectSerotoninergic mechanismsen_GB
dc.subjectNeurotransmittersen_GB
dc.subjectFluoxetine -- Therapeutic useen_GB
dc.subjectMolecular pharmacologyen_GB
dc.subjectClinical pharmacologyen_GB
dc.subjectDrugs -- Testingen_GB
dc.titleUnderstanding the molecular pharmacology of the serotonergic system : using fluoxetine as a modelen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1111/j.2042-7158.2011.01384.x-
dc.publication.titleJournal of Pharmacy and Pharmacologyen_GB
Appears in Collections:Scholarly Works - FacM&SCPT



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.